Johnson and Johnson ( Johnson and Johnson )

Johnson and Johnson

Johnson and Johnson's picture

Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Johnson and Johnson press release, blog etc

01/05/2018 - 07:36 Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients Lives
01/03/2018 - 14:41 Dr. Paul Janssen Award for Biomedical Research Issues 2018 Call for Nominations to Celebrate Champions of Science
01/03/2018 - 06:21 LANDMARK SCHIZOPHRENIA DATA THAT BRINGS HOPE IN BREAKING THE CYCLE OF HOSPITALIZATION AND INCARCERATION RECEIVES FDA APPROVAL FOR INCLUSION IN INVEGA SUSTENNA (paliperidone palmitate) LABEL
12/21/2017 - 15:02 Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
12/21/2017 - 09:59 U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
12/12/2017 - 20:42 Janssen and Leading Advocacy Organizations Introduce Cancer.com, a Customizable Online Destination for People Impacted by Cancer
12/12/2017 - 08:31 DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
12/11/2017 - 18:35 Early data evaluated subcutaneous delivery of DARZALEX in relapsed or refractory multiple myeloma (oral presentation;
12/11/2017 - 05:42 Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
12/09/2017 - 17:02 Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3-Year Follow-Up Data of IMBRUVICA (ibrutinib)
12/04/2017 - 21:37 Phase 3 Study Evaluating IMBRUVICA (ibrutinib) in Combination with Rituximab in Waldenstroms Macroglobulinemia Met Primary Endpoint
11/30/2017 - 00:20 Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine
11/21/2017 - 14:54 Supplemental Biologics License Application (sBLA) seeks first indication for DARZALEX for the treatment of newly diagnosed patients
11/17/2017 - 12:15 EASEL is the first real-world study to show adults with type 2 diabetes and established cardiovascular disease (CVD) have a lower risk of major adverse cardiovascular events (MACE) with SGLT2i therapy
11/17/2017 - 08:32 OneTouch Launches #SmallVictories to Honor People Living with Diabetes with Unexpected Celebrations during Diabetes Awareness Month
11/14/2017 - 07:56 INVOKANA (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
11/13/2017 - 12:41 Johnson & Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Toughest Consumer Skincare Problems
11/07/2017 - 04:44 NEW PHASE 2 DATA SHOW TREATMENT WITH TREMFYA (GUSELKUMAB) IMPROVED PSORIATIC ARTHRITIS SYMPTOMS THROUGH ONE YEAR